Introduction
Fetal growth restriction (FGR) refers to fetuses not attaining biologically determined growth potential. 1 To date, the most widely used correlate of FGR has been an estimated fetal weight <10th percentile for gestational age (GA), otherwise known as small for GA (SGA). [2] [3] [4] Strictly speaking, FGR requires serial studies to document a change in growth trajectory while SGA is diagnosed largely based on birthweight or estimated fetal weight for GA. In the majority of cases, fetal SGA is due to a spectrum of chronic placental disease, commonly described by clinicians as "placental insufficiency." 5 Other causes of fetal SGA include genetic disorders, congenital anomalies, or infections. 5 Fetal SGA is associated with stillbirth, adverse neonatal outcomes, altered neurological and cognitive development, and potentially cardiovascular and endocrine diseases in adulthood, with significant social and economic implications. [6] [7] [8] [9] [10] Fetal SGA fetuses undergo substantial physiologic adaptation in response to fetal hypoxemia and nutrient deprivation [11] [12] [13] and thus may render standard perinatal and intrapartum interventions such as antenatal glucocorticoids or intrapartum magnesium sulfate less effective or ineffective and at times harmful. [14] [15] [16] Not surprisingly, management of pregnancies with FGR likely to deliver at preterm gestation remains an unresolved dilemma and there is subsequent wide variation in clinical practice. These variations include array of surveillance methods and very different parameters considered in contemplating management decisions such as timing of birth. 3, [17] [18] [19] In this article, we review: (1) the physiologic adaptions of SGA fetuses in relation to antenatal glucocorticoids; (2) A diagnosis of fetal growth restriction and subsequent preterm birth is associated with increased risks of adverse perinatal and neurodevelopmental outcomes and potentially long-lasting effects to adulthood. Most such cases are associated with placental insufficiency and the fetal response to chronic intrauterine hypoxemia and nutrient deprivation leads to substantial physiological and metabolic adaptations. The management of such pregnancies, especially with respect to perinatal interventions and birth mode, remains an unresolved dilemma. The benefits from standard interventions for threatened preterm birth may not be necessarily translated to pregnancies with small-for-gestational-age fetuses. Clinical trials or retrospective studies on outcomes following administration of antenatal glucocorticoids and magnesium sulfate for neuroprotection when preterm birth is imminent either have yielded conflicting results for small-for-gestational-age fetuses, or did not include this subgroup of patients. Experimental models highlight potential harmful effects of administration of antenatal glucocorticoids and magnesium sulfate in the pregnancies with fetal small for gestational age although clinical data do not substantiate these concerns. In addition, heterogeneity in definitions of fetal small for gestational age, variations in the inclusion criteria, and the glucocorticoid regime contribute to inconsistent results. In this review, we discuss the physiologic adaptions of the small-for-gestational-age fetus to its abnormal in utero environment in relation to antenatal glucocorticoids; the impact of antenatal glucocorticoids and intrapartum magnesium sulfate in pregnancies with fetal small for gestational age; the current literature on birth mode for pregnancies with fetal small for gestational age; and the knowledge gaps in the existing literature.
the impact of antenatal glucocorticoids and intrapartum magnesium sulfate for pregnancies with fetal SGA likely to deliver at preterm gestation; and (3) the mode of birth after suspected fetal SGA.
Fetal SGA and antenatal glucocorticoids Overview of benefits and concerns of antenatal glucocorticoid use in preterm births Antenatal glucocorticoids administration to improve newborn outcomes has become the mainstay of prophylactic treatment before anticipated preterm birth. 20, 21 In otherwise healthy fetuses, antenatal glucocorticoids promote pulmonary surfactant synthesis and secretion, enhance structural maturation of the alveoli to support postnatal lung function, increase lung compliance, and generate an enhanced response to postnatal surfactant treatment. 22 Glucocorticoids also have similar maturational effects on other fetal organs including the brain, kidneys, and intestine. 22 20 Currently a single course of glucocorticoids is recommended for pregnant women between 24 0 weeks (or 23 0 weeks, based on a family's decision regarding resuscitation) and 33 6 weeks of GA who are at risk of preterm birth within 7 days, including for those with ruptured membranes and multiple gestations. 23 For decades, it has been assumed that chronic intrauterine stress that occurs in tandem with fetal SGA may cause prolonged stimulation of adrenal gland, accelerate pulmonary maturation, and thus result in a lower risk for respiratory distress syndrome than appropriate-for-GA neonates. 24 This rationale implies that growth-restricted fetuses may not benefit from antenatal corticosteroids in contrast with appropriately grown fetuses.
Pathophysiological changes associated with fetal SGA in relation to antenatal glucocorticoids The effects of glucocorticoids are complex in the setting of fetal SGA, and both basic and translational science studies have raised specific concerns in this regard ( Figure) .
First, chronic fetal stress associated with fetal SGA stimulate placental corticotropin-releasing hormone release. 25 Corticotropin-releasing hormone, 26 adrenocorticotrophic hormone, 26 and cortisol levels 27 are all significantly elevated in fetal SGA in a graded manner as shown in studies where the degree of hypoglycemia in fetuses correlated with the extent of placental vascular compromise. 28 Circulating levels of glucocorticoids can FIGURE Pathophysiological changes associated with fetal SGA in relation to antenatal glucocorticoids regulate vasomotor tone, brain perfusion, the response to exogenous steroids, and glucose homeostasis after birth. On the other hand, elevations of cortisol downregulate insulin like growth factor-I activity and may therefore have additional negative impacts on linear growth. 29 Second, fetal SGA is associated with reduced expression and function of 11b-hydroxysteroid dehydrogenase type 2 in the placenta, 30, 31 an enzyme in the pathway for conversion of cortisol to cortisone. Reduced cortisol to cortisone conversion leads to excessive transplacental transfer of maternal endogenous cortisol to the fetus. 14, 32 Third, elevated fetal cortisol levels, coupled with increased dosage (relative to fetal weight) or a more prolonged exposure to glucocorticoids, result in a switch in fetus from a state when cellular proliferation is needed for growth and cell differentiation to a state of programed cell death. 15, 33 Studies have demonstrated decreased fetal growth velocity and weight gain in both animal models and in neonates after glucocorticoids exposure, 34, 35 although the minor effect of corticosteroids on fetal growth velocity is transient and potentially does not affect long-term growth. 36 Fourth, there is conflicting evidence on the effect of exogenous glucocorticoids on lung growth and surfactant protein expression in different animal models of intrauterine growth restriction.
14 Despite transient improvement in umbilical artery enddiastolic flow in preterm fetal SGA following glucocorticoids administration, [37] [38] [39] the net effect may be neutral. Fifth, dexamethasone seems to be more potent in eliciting nongenomic effects than betamethasone in fetus as shown by a greater reduction in lung and liver weight after repetitive doses of dexamethasone. 15, 33 However, betamethasone might also selectively constrict the umbilical arteries and exacerbate these preexisting abnormalities in transplacental gas exchange. 40 Thus, both these agents have positive and negative effects and there is debate in literature regarding which agent might be better in these circumstances. 20 Finally, Miller et al 41 demonstrated that SGA fetuses displayed augmented carotid blood flow reperfusion in response to maternal betamethasone in comparison with healthy fetuses; this rebound perfusion correlated with lipid peroxidation and higher neuronal necrosis.
In summary, SGA carries major consequences for not only somatic growth, but also for regulation of the endocrine, respiratory, and cardiovascular systems. With the adaptive changes in the physiology of SGA fetuses, the efficacy and safety of the antenatal glucocorticoids have been questioned.
Antenatal corticosteroid use for pregnancies with fetal SGA: evidence from human studies There are conflicting results from studies addressing the efficacy of antenatal corticosteroids to improve preterm birth outcomes for SGA fetuses (Table) .
Bernstein et al 42 examined the association among SGA neonates, receipt of antenatal glucocorticoids, and neonatal outcomes in very low birthweight neonates in the Vermont Oxford Network database. They reported that antenatal glucocorticoid administration was associated with significantly lower risks of adverse outcomes in SGA neonates, and benefits were similar to that in non-SGA neonates. 42 A population-based study from the Israel Neonatal Network reported that antenatal glucocorticoids therapy was associated with significantly reduced mortality and morbidities among preterm SGA neonates. 43 A retrospective cohort study from the Canadian Neonatal Network revealed that, for preterm SGA neonates, exposure to antenatal corticosteroids 1-7 days before birth was associated with decreased odds of neonatal mortality and major morbidity, similar in magnitude to that observed among GA-matched non-SGA neonates. 44 A follow-up study of SGA neonates born between 26-32 weeks' gestation suggested that survival without disability or handicap at 2 years' corrected age was increased in children who received betamethasone as fetuses, compared with children who did not receive betamethasone, although there was a statistically significant negative effect of betamethasone on subsequent somatic growth 45 (Table) .
In contrast, some studies reported no effects of antenatal corticosteroids on neonatal morbidity or mortality among SGA infants. [46] [47] [48] [49] van Stralen et al, 46 in a retrospective cohort study, reported that the prevalence of adverse neonatal outcomes did not differ between severely preterm SGA fetuses with and without exposure to antenatal corticosteroids. Ley et al 48 and Elimian et al 47 also reported no additional benefits for mortality and shortterm morbidities in SGA exposed to antenatal corticosteroids. Mitsiakos et al 49 identified that SGA fetuses exposed to antenatal corticosteroids exhibited a higher incidence of severe global delay (those who scored 2 SD below average in all parameters in Griffiths test) than the nonexposed group (Table) .
Gaps of knowledge and recommendations
In summary, the results published so far regarding the benefits of antenatal corticosteroids in the fetal SGA subgroup are inconsistent, likely because of heterogeneity in the definitions, inclusion criteria, and the steroid regime for SGA. 50 To date, there are no randomized studies specifically designed to assess the effect of antenatal corticosteroids in fetal SGA. The efficacy considerations are based on prospective or retrospective cohorts and small casecontrol studies. 15 In daily clinical practice, SGA fetuses frequently become exposed to exogenous corticosteroids when preterm birth is anticipated. 15 The following gaps of knowledge need to be urgently addressed in future clinical studies: (1) what are the neonatal morbidities associated with exposure of SGA fetuses to repeated courses of antenatal corticosteroids; (2) pass the routine window of benefit of 7 days before birth.
Based on the current clinical evidence, it is reasonable to give a single course of glucocorticoids to pregnant women with growth-restricted fetuses who are at risk of preterm birth within 7 days; however, this intervention needs to be combined with enhanced fetal surveillance. 51 There is insufficient evidence to conclude whether repeated or rescue antenatal corticosteroids administration is beneficial or harmful for this group of infants. Furthermore, existing data in the literature do not allow us to recommend either betamethasone or dexamethasone as the preferable corticosteroid, which may be answered when results of an ongoing trial are available, although this trial is not exclusively focused on FGR fetuses. 52 Fetal SGA and magnesium sulfate Both preterm birth and fetal SGA are associated with higher risk of cerebral palsy.
53 Neurodevelopmental morbidities associated with preterm birth include cerebral palsy, developmental delay, hearing and visual deficits, and behavioral issues. Animal studies revealed abnormal neuronal migration, reduced numbers of neurons in the hippocampus and the cerebellum, and retarded dendritic and axonal growth in preterm fetuses as potential reasons for neurological and behavioral deficits. 54, 55 Perinatal brain injury in preterm neonates is related to both white matter and neuronal injury and is suspected in part to be secondary to the release of proinflammatory cytokines and oxygen-free radicals. 56 Fetal SGA has been shown to be associated with a severe reduction in cortical growth and a significant decrease in cell number in the future cortex. 57 Magnesium sulfate administered during the intrapartum period exerts neuroprotective effects presumably through the following mechanisms: competitively reducing intracellular calcium entry, blocking glutamate and other excitatory neurotransmitter receptors responsible for neuronal death, and modulating the actions of proinflammatory cytokines and oxygen-free radicals. [58] [59] [60] [61] It is readily transferred across the placenta into fetal circulation within an hour of administration and has therefore prompted investigators to assess its role in fetal neuroprotection. Following the publication of several major clinical trials assessing the efficacy of intrapartum magnesium administration, [62] [63] [64] [65] a Cochrane review confirmed the neuroprotective role of magnesium sulfate given to women at risk of preterm birth, with reduced risk of cerebral palsy (RR, 0.68; 95% CI, 0.54e0.87) and substantial gross motor dysfunction (RR, 0.61; 95% CI, 0.44e0.85). 66 In all, 63 women needed to be treated with intrapartum magnesium sulfate to prevent 1 child from developing cerebral palsy. A recently published individual participant data meta-analysis, again, yielded a similar conclusion regarding the impact of antenatal magnesium sulfate to reduce the combined risk of fetal/ infant death or cerebral palsy, and the benefit is seen regardless of the reason for preterm birth. 67 Furthermore, antenatal magnesium sulfate exposure was independently associated with a decreased risk (odds ratio, 0.18; 95% CI, 0.049e0.65) of magnetic resonance imagingedetected cerebellar hemorrhage in preterm infants of <33 weeks' gestation. 68 However, some concerns have been expressed regarding the potential for intestinal injury following administration of magnesium sulfate. 69 A large population-based study reported no association between antenatal exposure to magnesium sulfate and necrotizing enterocolitis or spontaneous intestinal perforation in extremely preterm infants after adjustment for confounding variables, including SGA. 70 Guidelines from professional societies recommend that magnesium sulfate administration should be considered for women with imminent preterm birth, although there are variations in the upper limit of GA for which it has been suggested (<32 vs <30 weeks). 56, [71] [72] [73] Important to the context of this review is that none of the recommendations specify magnesium sulfate administration guidelines when fetal SGA is suspected.
None of the clinical trials specifically analyzed the outcomes of pregnancies expressed to magnesium sulfate with fetal SGA. 62, 64, 65, 74, 75 It is not currently known if administration of magnesium sulfate to pregnancies with fetal SGA can reverse the consequences of adverse brain growth as some of the processes for neuronal injury described above may already have been established especially if fetal Doppler abnormalities are already present. 76 Higher borderline cord blood ionized magnesium levels were observed in term growth-restricted fetuses compared with healthy term newborns, 55 although the mechanism for this increase was incompletely understood. Additional intrapartum administration could in theory lead to toxic levels of magnesium in SGA fetuses and could on the contrary be neurotoxic. 54 By contrast, magnesium is reported to suppress production of inflammatory cytokine and chemokine levels in preterm fetuses, and have vasodilatory effects that potentially improve uterine blood flow, 77 which is affected in pregnancies with SGA fetuses. 78 Roman et al, 77 in a rat model, reported that continuous oral maternal magnesium supplementation throughout gestation was accompanied by a significant decrease in the incidence of fetal SGA. Gao and Zou 79 reported that subcutaneous administration of magnesium to maternal rats with induced fetal SGA by exposure to smoking led to a dosedependent improvement in fetal weight, an effect thought to be due to conserved placental function secondary to decreased in apoptosis of trophoblasts via reduced expression of caspase-3.
In summary, there is insufficient evidence to recommend for or against the administration of magnesium sulfate for neuroprotection to women at risk of preterm birth with a SGA fetus. At this point, evidence is lacking with respect to the following: (1) the effectiveness and safety profile of magnesium sulfate for neuroprotection in pregnancies carrying a fetus suspected of having fetal SGA; (2) the GA below which this therapy should be offered; (3) the optimal loading and ajog.org Expert Reviews maintenance doses; (4) the impact of magnesium sulfate administration on early neurodevelopmental outcomes among preterm fetal SGA; and (5) the effect of magnesium sulfate administration on neurodevelopmental outcomes >2 years of age, especially learning disabilities and developmental coordination disorder in pregnancies affected by fetal SGA.
Fetal SGA and mode of birth Near-term fetal SGA The main challenge in the management of pregnancies with fetal SGA is to predict which fetuses can tolerate induction of labor (IOL) safely and which fetuses should have a planned cesarean birth. Among term appropriately grown fetuses, planned cesarean birth is not recommended <39 0 weeks' gestation due to the higher risk of respiratory complications compared to vaginal births. 80 The DIGITAT trial randomized 650 pregnancies with suspected fetal SGA (defined as an estimated fetal weight <10th centile) at 36-38 weeks' gestation to birth by IOL or to delayed birth (mean 10 days) with fetal monitoring. 81 At randomization, >97% in each arm had normal umbilical artery Doppler waveforms. The rates of cesarean birth (14% vs 13.7%) were very similar in both arms of the study and were mostly performed for suspected fetal compromise (82% vs 89%). Predefined composite neonatal outcomes were similar in both arms (5.3% vs 6.1%). These data suggest that near-term fetuses with suspected fetal SGA and normal umbilical artery Doppler can safely tolerate IOL.
In a single-center retrospective study of 836 women with suspected fetal SGA and a significantly higher emergency cesarean birth rate of 43%, the rate of neonatal admission was higher with attempted vaginal birth (43% vs 29%) than in women who had a planned cesarean birth. 82 These findings contrast with a secondary analysis of the Cesarean Section Registry of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, which reported that SGA infants born to women who had a trial of labor before cesarean birth exhibited no difference in neonatal outcomes compared with those delivered by planned repeat cesarean birth (adjusted RR, 0.99; 95% CI, 0.88e1.12). 83 These findings may not apply to smaller newborns, since only 15-23% of SGA neonates in the 2 arms of the study were born at preterm gestation. 83 Several tests of fetal well-being have the potential to identify a subset of nearterm SGA fetuses that may benefit from planned cesarean delivery. The oxytocin challenge test (OCT) was developed in the pre-Doppler era, as a tool to avoid stillbirth and reduce the risk of severe fetal acidosis at vaginal birth by performing cesarean births in women exhibiting a positive test. 84 In 2003, a prospective Scandinavian study addressed the role of the OCT to direct mode of birth in 84 term fetuses with suspected FGR. 85 Pregnancies with absent end-diastolic flow in the umbilical arteries were excluded and underwent cesarean birth directly. Nineteen (23%) women in the cohort had a positive OCT that, by hospital protocol, also resulted in planned cesarean birth. Interestingly, umbilical artery Doppler waveforms did not predict the OCT result. Furthermore, among the remainder, the success of attempted vaginal birth (69% with abnormal vs 78% with normal waveforms) was also not predicted by umbilical artery Doppler. Several investigators, for example the multicenter PORTO group, 3 that prospectively evaluated >1100 pregnancies with suspected FGR, reported limited diagnostic utility of umbilical artery Doppler to predict adverse perinatal outcomes, which aligns with recent findings in a mouse model of SGA stillbirth at term. 86 The human near-term fetus protects oxygen delivery to the brain in the face of progressive hypoxemia by increasing cerebral blood flow. 87 This redistribution of fetal cardiac output is recognized noninvasively by increased diastolic flow velocities in the middle cerebral arteries (MCA), which reduces the waveform pulsatility index (PI). 88 The ratio of the PI in the MCA/umbilical artery is termed the "cerebroplacental ratio" (CPR). A subsequent PORTO group analysis identified the superiority of an abnormal CPR (<1.0) in comparison with umbilical artery Doppler to predict adverse perinatal outcomes. 89 Unfortunately, no specific data on mode of birth were presented, nor on the strength of the relationship between Doppler findings, fetal weight estimation, or the subsequent risk of emergency cesarean birth. A subsequent large retrospective cohort study demonstrated the association between CPR and an increased risk of operative birth for fetal compromise. 90 In Barcelona, among longitudinal Doppler studies of 171 late-onset fetal SGA cases, MCA Doppler was superior to umbilical artery Doppler for the subsequent prediction of birth due to an abnormal biophysical profile. 91 In 2011, the Scandinavian group reported the introduction of MCA Doppler into their protocol to manage term pregnancies with suspected fetal SGA, again excluding attempted vaginal delivery in pregnancies with highly abnormal umbilical artery Doppler waveforms. 92 OCT remained a gold standard test for planned cesarean birth, however MCA Doppler was not predictive of an abnormal OCT. The investigators justified ongoing use of the OCT to direct mode of birth due to the low (3%) overall rate of low Apgar scores and acidosis and a 63% successful vaginal birth rate. The OCT is not widely used as a discrete test of fetal well-being. However, as the cervical catheter option for IOL near term is gaining some popularity, and is increasingly combined with oxytocin, 93 then in a pragmatic sense OCTs are being performed when vaginal delivery is being attempted in near-term SGA pregnancies.
To guide clinicians using the above ultrasound information to manage pregnancies with late-onset FGR, a decision tool has been developed to predict the risk of perinatal morbidity and cesarean birth from analysis of a cohort of 509 pregnancies. 94 Any of 3 criteria (CPR <10th centile; estimated fetal weight <3rd centile; uterine artery Doppler mean PI >95th centile) resulted in a 3-to 4-fold increased risk of emergency cesarean birth (29% vs 8% Preterm FGR When FGR is suspected in earlier gestations, it commonly is associated with abnormal uterine artery Doppler, high rates of absent/reversed end-diastolic flow in the umbilical arteries, and significant placental pathology. 78 The severity of placenta-mediated FGR presenting with these placental Doppler findings commonly results in progressive alterations in both MCA and ductus venosus Doppler waveforms that correlate with progressive degrees of fetal hypoxia. 96 Uterine contractions in this context have been shown to provoke abnormal flow patterns in the uterine and umbilical arteries [97] [98] [99] and thus the reported rates of cesarean birth typically are >80%. 100 Consequently, many centers now use absent/reversed enddiastolic flow as an indication for elective cesarean birth in this context. 101 Interestingly, the TRUFFLE trial, comparing safety of monitoring of the preterm FGR fetus by ductus venosus Doppler and computerized nonstress test, did not standardize mode of birth and did not report rates of cesarean birth.
102 Data from National Center for Health Statistics identified cesarean birth rates of 50-67% for SGA neonates and 22-38% for appropriate-for-GA neonates of 26-32 weeks of gestation in vertex presentation. 103 Cesarean birth was associated with a survival advantage for preterm SGA neonates between 26-30 weeks' gestation after adjustment for sociodemographic and medical factors (odds ratio, 2.8; 95% CI, 2.2e3.5). 103 However, confounding by indication cannot be ruled out.
Conclusions
Despite substantial advances in neonatal care, many unresolved issues remain regarding key decisions for the optimal management of pregnancies complicated by SGA fetuses, especially when preterm delivery is contemplated. Substantial physiologic adaptations made by the preterm SGA fetus to an unfavorable environment have the potential to render proven beneficial treatments questionable in management of preterm birth in fetal SGA, such as antenatal glucocorticoids and magnesium sulfate for neuroprotection. Such interventions deserve specific evaluation in suspected fetal SGA. The widespread application of fetal Doppler studies in the assessment of preterm SGA fetuses has resulted in improved clinical outcomes, largely from improved prenatal diagnosis and in utero transfer of such pregnancies to tertiary care facilities. Despite substantial advances in effective noninvasive fetal monitoring methods to safely prolong pregnancy, especially the application of fetal Doppler studies, the ultimate obstetric intervention of delivery mode has surprisingly received minimal attention. Further research is encouraged to aid clinicians in the decision between IOL and planned cesarean birth for the pregnancies with suspected SGA fetus. Standardization of definitions, monitoring methods, and the design of adequately powered studies are urgently needed to further improve outcomes in these high-risk pregnancies. Questions regarding: (1) neonatal morbidities and neurocognitive outcomes associated with SGA fetuses exposed to single or repeated courses of antenatal corticosteroids; and (2) effectiveness and safety profile of magnesium sulfate for neuroprotection in pregnancies carrying a fetus suspected of having fetal SGA need to be addressed in future clinical studies.
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